中国脑血管病临床管理指南（第2版）（节选）——第4章 缺血性脑血管病临床管理推荐意见 Chinese Stroke Association Guidelines for Clinical Management of Cerebrovascular Diseases (Second Edition) (Excerpt)——Chapter Four Clinical Management of Ischaemic Cerebrovascular Diseases

Abstract

我国的卒中发病率仍在持续上升，每年新发病例占全球的四分之一。在我国40岁及以上的人群中，缺血性卒中约占所有卒中类型的86.8%。自2019年中国脑血管病临床管理指南发布以来，缺血性卒中急性期再灌注治疗及二级预防抗血小板治疗等领域取得了多项进展。本指南就缺血性卒中急性期评估及诊断、再灌注治疗、抗血小板治疗、其他治疗、常规支持治疗及并发症管理、病因及发病机制的早期评估和诊断、针对病因和发病机制的干预、危险因素管理及长期干预更新推荐意见。 Abstract: The incidence of stroke in the Chinese population is still on the rise, accounting for nearly one-fourth of the global annual stroke cases. Among adults aged 40 or above in China, ischaemic stroke (IS) accounted for approximately 86.8% of all strokes. Since the publication of the 2019 Chinese Stroke Association guidelines, notable advancements have emerged in acute-phase reperfusion therapy and antiplatelet treatments for secondary prevention in IS. The guidelines have provided updated recommendations on evaluation and diagnosis of acute phase of ischaemic stroke, reperfusion therapy, antiplatelet therapy, other treatments in the acute phase, general supportive treatment and complications management, early evaluation and diagnosis of aetiology and pathogenesis, interventions targeting aetiology and pathogenesis, risk factors management, and long-term intervention.

Keywords

• 缺血性卒中
• 再灌注治疗
• 抗血小板治疗
• 病因学
• 危险因素
• ischaemic stroke
• reperfusion therapy
• antiplatelet therapy
• aetiology
• risk factor